A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache
The main purpose of this study is to evaluate whether the study drug known as galcanezumab is
 safe and effective in the prevention of migraine headaches.
Inclusion Criteria:

 -  Participants with a history of migraine of at least 1 year prior to enrollment.

 -  Migraine onset prior to age 50.

 Exclusion Criteria:

 -  Current enrollment in, or discontinuation within the last 30 days from, a clinical
 trial involving any investigational drug or device.

 -  Current use or any prior exposure to any CGRP antibody, any antibody to the CGRP
 receptor, or antibody to nerve growth factor (NGF).

 -  History of migraine subtypes including hemiplegic migraine, ophthalmoplegic migraine,
 and basilar-type migraine.

 -  Have a history or presence of other medical illness that indicates a medical problem
 that would preclude study participation.

 -  Failure to respond to more than two adequately dosed effective migraine prevention
 treatments.

 -  Evidence of significant active psychiatric disease, in the opinion of the
 investigator.

 -  Women who are pregnant or nursing.